Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections

PD Tamma, SL Aitken, RA Bonomo… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …

Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …

PD Tamma, SL Aitken, RA Bonomo… - Clinical infectious …, 2022 - academic.oup.com
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …

Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem …

PD Tamma, SL Aitken, RA Bonomo… - Clinical Infectious …, 2022 - academic.oup.com
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …

Global threat of carbapenem-resistant gram-negative bacteria

SS Jean, D Harnod, PR Hsueh - Frontiers in cellular and infection …, 2022 - frontiersin.org
Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …

Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance

S Karakonstantis, M Rousaki, EI Kritsotakis - Antibiotics, 2022 - mdpi.com
Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms
(including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon …

Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii

M Falcone, G Tiseo, A Leonildi… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter
baumannii (CRAB) infections, but clinical data are limited. This is an observational …

Catheter-associated urinary tract infections: current challenges and future prospects

GT Werneburg - Research and reports in urology, 2022 - Taylor & Francis
Catheter-associated urinary tract infection (CAUTI) is the most common healthcare-
associated infection and cause of secondary bloodstream infections. Despite many …

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus …

KS Kaye, AF Shorr, RG Wunderink, B Du… - The Lancet Infectious …, 2023 - thelancet.com
Background An urgent need exists for antibiotics to treat infections caused by carbapenem-
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections

RK Shields, DL Paterson… - Clinical Infectious …, 2023 - academic.oup.com
Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

Advances in the microbiology of Stenotrophomonas maltophilia

JS Brooke - Clinical microbiology reviews, 2021 - Am Soc Microbiol
Stenotrophomonas maltophilia is an opportunistic pathogen of significant concern to
susceptible patient populations. This pathogen can cause nosocomial and community …